- Home
- CATO vs OTLK Comparison
CATO vs OTLK Comparison
Compare CATO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- OTLK
- Stock Information
- Founded
- CATO 1946
- OTLK 2010
- Country
- CATO United States
- OTLK United States
- Employees
- CATO N/A
- OTLK N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CATO Consumer Discretionary
- OTLK Health Care
- Exchange
- CATO Nasdaq
- OTLK Nasdaq
- Market Cap
- CATO 55.7M
- OTLK 48.3M
- IPO Year
- CATO N/A
- OTLK 2016
- Fundamental
- Price
- CATO $2.56
- OTLK $1.84
- Analyst Decision
- CATO
- OTLK Strong Buy
- Analyst Count
- CATO 0
- OTLK 5
- Target Price
- CATO N/A
- OTLK $10.20
- AVG Volume (30 Days)
- CATO 43.9K
- OTLK 696.2K
- Earning Date
- CATO 05-22-2025
- OTLK 05-15-2025
- Dividend Yield
- CATO 13.28%
- OTLK N/A
- EPS Growth
- CATO N/A
- OTLK N/A
- EPS
- CATO N/A
- OTLK 0.83
- Revenue
- CATO $642,949,000.00
- OTLK N/A
- Revenue This Year
- CATO N/A
- OTLK N/A
- Revenue Next Year
- CATO N/A
- OTLK $288.46
- P/E Ratio
- CATO N/A
- OTLK $2.22
- Revenue Growth
- CATO N/A
- OTLK N/A
- 52 Week Low
- CATO $2.19
- OTLK $0.87
- 52 Week High
- CATO $6.70
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- CATO 47.88
- OTLK 62.17
- Support Level
- CATO $2.50
- OTLK $1.55
- Resistance Level
- CATO $2.89
- OTLK $1.73
- Average True Range (ATR)
- CATO 0.19
- OTLK 0.18
- MACD
- CATO 0.01
- OTLK 0.01
- Stochastic Oscillator
- CATO 28.85
- OTLK 65.49
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.